stockportfolio.pro logostockportfolio.pro
Stocks Screener Start 7-day free trial
Stocks / PTGX / Net Income

Protagonist Therapeutics, Inc. Net Income 2014–2025

Protagonist Therapeutics, Inc. (PTGX) annual net income by fiscal year, computed from SEC filings.

Fiscal yearNet IncomeNet marginChange (YoY)
FY 2025$-130.15M-282.8%-147.3%
FY 2024$275.19M63.3%+448.5%
FY 2023$-78.95M-131.6%+38.0%
FY 2022$-127.39M-479.3%-1.5%
FY 2021$-125.55M-458.9%-89.8%
FY 2020$-66.15M-231.1%+14.3%
FY 2019$-77.19M-33414.3%-98.3%
FY 2018$-38.92M-125.9%-5.3%
FY 2017$-36.96M-184.2%+0.6%
FY 2016$-37.18M-150.2%
FY 2015$-14.86M-34.2%
FY 2014$-11.07M

Source: Protagonist Therapeutics, Inc. SEC filings — income statement (10-K). Refreshed nightly.

See the full picture for Protagonist Therapeutics, Inc.

Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.

Open the interactive view — free

Protagonist Therapeutics, Inc. — frequently asked questions

What is Protagonist Therapeutics, Inc.'s net income?

Protagonist Therapeutics, Inc. (PTGX) reported net income of $-130.15M for fiscal year 2025, per its SEC filings.

Where does this data come from?

Figures are computed from Protagonist Therapeutics, Inc.'s official SEC filings (income statement (10-K)), refreshed nightly. Not investment advice.

More PTGX financial history

Full PTGX fundamentals page → · All 1,500+ companies →